MEET THE TEAM
Professor Sidney Altman
NOBEL PRIZE WINNER
Nobel Prize winner in chemistry (1989) for his discoveries concerning the catalytic properties of RNA. Sterling Professor of Molecular, Developmental, and Cellular Biology and Chemistry at Yale University, specializes in molecular biology, he worked in renowned universities such as Harvard, Yale and Cambridge.
Professor Arieh Warshel
NOBEL PRIZE WINNER
Nobel Prize winner in chemistry (2013) for the development of multiscale models for complex chemical systems. Professor Warshel is a pioneer in computational studies on functional properties of biological molecules. Distinguished Professor of Chemistry and Biochemistry at University of Southern California in Los Angeles, USA, also worked in other renowned research institutes, such as Weizmann Institute of Science, Israel and the Laboratory of Molecular Biology at Cambridge, England.
Professor Stefan Bornstein
Director of the Centre for Internal Medicine and the Medical Clinic and Policlinic III at the University Hospital Carl Gustav Carus of the Technical University of Dresden as well as the medical faculty’s vice dean of international affairs and development and a member of the supervisory board of the University Hospital of Dresden. He is also the chair and honorary consultant for diabetes and endocrinology at King’s College London.
Professor Gil Lebiowitz
Senior Physician in the Endocrinology and Metabolism Service, Hadassah Medical Centre, Chairman of the Diabetes mellitus study centre in the Hebrew University.
Professor Eduardo Mitrani
INVENTOR OF BETALIN'S TECHNOLOGY
Professor of Developmental Biology at the Institute of Life Sciences at the Hebrew University of Jerusalem. Specializes in tissue engineering and adult tissue repair and regeneration.
BOARD OF DIRECTORS
Mr. Joshua Hershcovich
CHAIRMAN AND FOUNDER
Mr. Hershcovich is the Chairman of the Board. He has vast hands-on experience in capital markets, mergers and acquisitions, and developing public companies from a financial and entrepreneurial perspective
Mr. Shay Hershcovich
Mr. Hershcovich is an investment strategist with a BA and MBA in Business Management. He manages the company’s investment strategy and supports its Business Development activities
Mr. Zohar Pinhasi
A former IT security intelligence officer for the Israeli military, Mr. Pinhasi is the founder and CEO of MonsterCloud, a leader in ransomware removal and managed cyber security services backed by former FBI Deputy Director John Pistole. Mr. Pinhasi is an avid anti-ransomware advocate, providing cyber threat intelligence to some of the world’s top authorities, including The Federal Bureau of Investigation (FBI) and dozens of police departments and municipalities across the United States.
Mr. Cao Kun
Mr. Kun is the Director of International Cooperation & Investment, Zhongguancun Medical Engineering & Translation Center (MTP). He is specialized in the investment, financing, innovation management and business development of the advanced technology/product and SMEs in the field of healthcare/life science.
Mr. Asaf Bartfeld
Mr. Bartfeld has served as the Chief Executive and President of Delek Group, one of the largest Energy Companies in Israel since 2013. Bartfeld retired from Delk Group at the end of 2019 after serving in various functions at the company for more than 30 years including the CFO of Delek Geoup. Bartfeld has held several senior positions at Delek Group during his time at the company, including Chairman or director in several Delek Group subsidiaries and affiliates including companies in the USA and England.
OUR TEAM
Mr. David Nitsan
CEO
Mr. Nitsan has over 15 years of experience as a global CEO, transforming companies into market leaders while driving profits and achieving growth targets. His background spans the medical device, technology, and high tech industries, directing start-ups from idea to commercialization, M&A (EXIT) through fundraising, tactical negotiation, and due diligence.
Ms. Tehila Hyman
CTO
Ms. Tehila is a highly experienced CEO and VP of R&D with a demonstrated history in managing End-to-End R&D processes in medical devices and pharma companies. She has a proven ability to lead international preclinical & clinical trials, meet US & EU regulations, and manage multidisciplinary R&D teams and cutting-edge technology research.